<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740255</url>
  </required_header>
  <id_info>
    <org_study_id>1115</org_study_id>
    <nct_id>NCT04740255</nct_id>
  </id_info>
  <brief_title>Epistamp for Postinflammatory Hyperpigmentation</brief_title>
  <acronym>EPH</acronym>
  <official_title>Clinical Trial Study for the Use of Epistamp Needling Device to Treat Postinflammatory Hyperpigmentation (PIH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universal Skincare Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lavish Beauty</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universal Skincare Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will expand knowledge and application needling using the Epistamp device for&#xD;
      the improvement of Postinflammatory Hyperpigmentation (PIH) caused by acne.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will expand the knowledge and application of needling using the Epistamp&#xD;
      device and its safety and benefits for improving the appearance of Postinflammatory&#xD;
      Hyperpigmentation. Postinflammatory Hyperpigmentation (PIH) caused by acne is a common&#xD;
      inflammatory disease that can adversely affect facial appearance. Facial acne can have a&#xD;
      serious negative impact on psychosocial functioning leaving deep emotional scars. Severe acne&#xD;
      can also lead to physical scars and disfigurement. Among patients with severe acne, facial&#xD;
      scarring affects both genders equally and occurs to some degree in 95% of cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2021</start_date>
  <completion_date type="Anticipated">September 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants in the Epistamp trial are those who are seeking improvement for Postinflammatory Hyperpigmentation (PIH) caused by acne.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Skin improvement assessed by Derma Scan</measure>
    <time_frame>6 months</time_frame>
    <description>The Derma Scan System utilizes two special lighting systems (RGB +UV) and smart skin analyzer software that allows two images (before and after care) to be compared side by side, which can be used to detect the changes in skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Skin improvement assessed by Post Acne Hyperpigmentation Index (PAHPI)</measure>
    <time_frame>6 months</time_frame>
    <description>The parameters of the scoring method are: median lesion size (S) (&lt;3mm, 3-6, 7-10, and &gt;10mm scored as 2, 4, 6, and 8, respectively), median lesion intensity (I) (slightly or moderately or significantly darker than surrounding skin scored as 3, 6, and 9, respectively), and number of lesions (N) (1-15, 16-30, 31-45, 46-60, and &gt;60 scored as 1-5, respectively). The score range from the total of S+I+N=6-22.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>6 months</time_frame>
    <description>The Global Aesthetic Improvement Scale (GAIS) is a 5-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator 5 point scale ranging from 1 to 5 with 5 = The appearance has worsen compared with the original condition and 1 = Excellent corrective results&#xD;
compared to pretreatment, as judged by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photographs</measure>
    <time_frame>6 months</time_frame>
    <description>Digital imaging device using a grid background with controlled lighting and setting to grade acne scar improvement on a quartile grading scale(1 = 1% to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = &gt;76% improvement).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the impact on the quality of life (DLQI)</measure>
    <time_frame>6 months</time_frame>
    <description>The Dermatology Life Quality Index questionnaire (DLQI) is 10 questions were asked to the patients and score is 0-3 for each question. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Postinflammatory Hyperpigmentation</condition>
  <arm_group>
    <arm_group_label>Epistamp Needling Treatment Without RF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Epistamp needling without RF (Radio Frequency)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epistamp Microneedling Treatment With RF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Epistamp needling with RF (Radio Frequency)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epistamp</intervention_name>
    <description>The patient's entire face will be treated. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm</description>
    <arm_group_label>Epistamp Microneedling Treatment With RF</arm_group_label>
    <arm_group_label>Epistamp Needling Treatment Without RF</arm_group_label>
    <other_name>Microneedling</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores.&#xD;
&#xD;
          -  Patients willing to sign informed consent.&#xD;
&#xD;
          -  Patients willing to be photographed and video documented&#xD;
&#xD;
          -  Patients willing to consent to 3 months of treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of eczema in the treatment area; psoriasis and any other chronic skin&#xD;
             conditions&#xD;
&#xD;
          -  History of actinic (solar) keratosis in the treatment area;&#xD;
&#xD;
          -  History of hemophilia&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  The presence of raised moles, warts on the targeted area.&#xD;
&#xD;
          -  Collagen vascular diseases or cardiac abnormalities&#xD;
&#xD;
          -  Blood clotting problems&#xD;
&#xD;
          -  Active bacterial or fungal infection&#xD;
&#xD;
          -  Facial melanosis&#xD;
&#xD;
          -  Malignant tumors&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Use of blood thinners or prednisone&#xD;
&#xD;
          -  Corticosteroids within two weeks of the procedure&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Porphyria or other skin diseases.&#xD;
&#xD;
          -  Patient not willing to sign informed consent.&#xD;
&#xD;
          -  TCA peels in the last 5 weeks&#xD;
&#xD;
          -  Subject currently has moderate to severe acne on the face.&#xD;
&#xD;
          -  Microneedling within the last 6 months&#xD;
&#xD;
          -  Subject has an active infection.&#xD;
&#xD;
          -  Subject has a history of a bleeding disorder&#xD;
&#xD;
          -  Subject has a history of keloidal tendency&#xD;
&#xD;
          -  Subject has received ablative or non-ablative laser treatments in the previous 6&#xD;
             months.&#xD;
&#xD;
          -  Subject has taken Accutane within the previous 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice E Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie L Nesbitt</last_name>
    <role>Study Chair</role>
    <affiliation>Universal Skincare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Jenkins, Tech</last_name>
    <phone>6468384154</phone>
    <email>trials@universalskincareinstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Nesbitt</last_name>
    <phone>6468384154</phone>
    <email>trials@universalskincareinstitute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lavish</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Wong, MD</last_name>
      <phone>646-838-4154</phone>
      <email>info@universalskincareinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Leslie Nesbitt</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://universalskincareinstitute.com/</url>
    <description>Description Derma Scan</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958495/</url>
    <description>Description Acne Scars Subtypes</description>
  </link>
  <results_reference>
    <citation>Goodman GJ, Baron JA. Postacne scarring: a qualitative global scarring grading system. Dermatol Surg. 2006 Dec;32(12):1458-66.</citation>
    <PMID>17199653</PMID>
  </results_reference>
  <results_reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>needling</keyword>
  <keyword>postinflammatory hyperpigmentation</keyword>
  <keyword>Epistamp</keyword>
  <keyword>Universal Skincare Institute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Once the overall trial is completed and sensitive detailed information is legally advised to published.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

